Triodos Investment Management BV Purchases 67,000 Shares of The Cooper Companies, Inc. $COO

Triodos Investment Management BV increased its position in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 37.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 248,000 shares of the medical device company’s stock after buying an additional 67,000 shares during the period. Triodos Investment Management BV owned 0.12% of Cooper Companies worth $17,648,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. JPMorgan Chase & Co. raised its stake in shares of Cooper Companies by 3.4% in the 1st quarter. JPMorgan Chase & Co. now owns 5,177,008 shares of the medical device company’s stock valued at $436,681,000 after buying an additional 172,485 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Cooper Companies by 17.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,734,327 shares of the medical device company’s stock valued at $399,340,000 after purchasing an additional 686,751 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Cooper Companies by 12.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,954,877 shares of the medical device company’s stock valued at $333,595,000 after purchasing an additional 425,400 shares during the last quarter. Millennium Management LLC boosted its stake in shares of Cooper Companies by 36.0% in the 1st quarter. Millennium Management LLC now owns 2,577,416 shares of the medical device company’s stock valued at $217,405,000 after purchasing an additional 682,166 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Cooper Companies by 15.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,121,835 shares of the medical device company’s stock valued at $178,977,000 after acquiring an additional 284,943 shares during the period. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, COO Daniel G. Mcbride acquired 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 2nd. The shares were bought at an average cost of $65.04 per share, for a total transaction of $195,120.00. Following the completion of the transaction, the chief operating officer owned 63,120 shares in the company, valued at approximately $4,105,324.80. This trade represents a 4.99% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Lawrence Erik Kurzius purchased 2,000 shares of Cooper Companies stock in a transaction on Monday, September 29th. The shares were acquired at an average price of $68.39 per share, for a total transaction of $136,780.00. Following the completion of the transaction, the director directly owned 5,777 shares of the company’s stock, valued at approximately $395,089.03. The trade was a 52.95% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased 17,975 shares of company stock valued at $1,216,346 in the last 90 days. 1.98% of the stock is owned by company insiders.

Analyst Ratings Changes

COO has been the topic of several research analyst reports. Morgan Stanley set a $76.00 target price on shares of Cooper Companies and gave the stock an “equal weight” rating in a report on Thursday, August 28th. Robert W. Baird reduced their price objective on shares of Cooper Companies from $97.00 to $85.00 and set an “outperform” rating for the company in a research report on Thursday, August 28th. Piper Sandler dropped their target price on Cooper Companies from $105.00 to $83.00 and set an “overweight” rating for the company in a report on Thursday, August 28th. UBS Group raised Cooper Companies to a “buy” rating in a research note on Tuesday, June 17th. Finally, Wall Street Zen downgraded Cooper Companies from a “buy” rating to a “hold” rating in a research note on Saturday, July 12th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Cooper Companies presently has an average rating of “Moderate Buy” and an average price target of $84.75.

Cooper Companies Price Performance

COO opened at $69.75 on Friday. The firm’s fifty day moving average price is $69.48 and its two-hundred day moving average price is $73.83. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.12 and a quick ratio of 1.24. The company has a market capitalization of $13.87 billion, a price-to-earnings ratio of 34.36, a P/E/G ratio of 1.84 and a beta of 1.02. The Cooper Companies, Inc. has a 1 year low of $61.78 and a 1 year high of $109.37.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings results on Wednesday, August 27th. The medical device company reported $1.10 earnings per share for the quarter, topping analysts’ consensus estimates of $1.07 by $0.03. Cooper Companies had a net margin of 10.08% and a return on equity of 9.82%. The company had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same period in the previous year, the firm earned $0.96 EPS. The firm’s quarterly revenue was up 5.7% on a year-over-year basis. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. As a group, analysts anticipate that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Cooper Companies announced that its Board of Directors has approved a share repurchase program on Wednesday, September 17th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical device company to buy up to 15.4% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s leadership believes its stock is undervalued.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.